The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 53095/0034.
IVEMEND 150 mg powder for solution for infusion
IVEMEND® 150 mg powder for solution for infusion
1. What IVEMEND is and what it is used for
2. What you need to know before you use IVEMEND
3. How to use IVEMEND
4. Possible side effects
5. How to store IVEMEND
6. Contents of the pack and other information
IVEMEND contains the active substance fosaprepitant which is converted to aprepitant in your body. It belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists". The brain has a specific area that controls nausea and vomiting. IVEMEND works by blocking signals to that area, thereby reducing nausea and vomiting. IVEMEND is used in adults, adolescents, and children aged 6 months or older in combination with other medicines to prevent nausea and vomiting caused by chemotherapy (cancer treatment) that is a strong or moderate trigger of nausea and vomiting.
Talk to your doctor, pharmacist, or nurse before using IVEMEND.
Before treatment with this medicine, tell your doctor if you have liver disease because the liver is important in breaking down the medicine in the body. Your doctor may therefore have to monitor the condition of your liver.
Do not give IVEMEND to children under 6 months of age or who weigh less than 6 kg, because it has not been studied in this population.
IVEMEND can affect other medicines both during and after treatment with IVEMEND. There are some medicines that should not be taken with IVEMEND (such as pimozide, terfenadine, astemizole, and cisapride) or that require a dose adjustment (see also ‘Do not use IVEMEND’).
The effects of IVEMEND or other medicines might be influenced if you take IVEMEND together with other medicines including those listed below. Please talk to your doctor or pharmacist if you are taking any of the following medicines:
Tell your doctor about any other medicines or herbal medicines you are taking, have recently taken, or might take.
This medicine should not be used during pregnancy unless clearly necessary. If you are pregnant or breast-feeding, may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this medicine.
For information regarding birth control, see ‘Other medicines and IVEMEND’.
It is not known whether IVEMEND is excreted in human milk; therefore, breast-feeding is not recommended during treatment with this medicine. It is important to tell your doctor if you are breast-feeding or are planning to breast-feed before receiving this medicine.
It should be taken into account that some people get dizzy and get sleepy after using IVEMEND. If you get dizzy or get sleepy, avoid driving or using machines after using this medicine (see ‘Possible side effects’).
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.
In adults (18 years of age and older), the recommended dose of IVEMEND is 150 mg fosaprepitant on Day 1 (day of chemotherapy).
In children and adolescents (6 months to 17 years of age), the recommended dose of IVEMEND is based on the patient’s age and weight. Depending on the chemotherapy treatment, there are two ways IVEMEND may be given:
IVEMEND is given only on Day 1 (single day of chemotherapy)
IVEMEND is given on Day 1, 2, and 3 (single or multiple days of chemotherapy)
The powder is reconstituted and diluted before use. The solution for infusion is given to you by a health care professional, such as a doctor or nurse, via an intravenous infusion (a drip) approximately 30 minutes before you start the chemotherapy treatment in adults or 60 – 90 minutes before you start the chemotherapy treatment in children and adolescents. Your doctor may ask you to take other medicines including a corticosteroid (such as dexamethasone) and a ‘5HT3 antagonist’ (such as ondansetron) for preventing nausea and vomiting. Check with your doctor or pharmacist if you are not sure.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Other side effects that have been reported are listed below.
Common side effects (may affect up to 1 in 10 people) are:
Uncommon side effects (may affect up to 1 in 100 people) are:
Rare side effects (may affect up to 1 in 1,000 people) are:
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The first 2 numbers indicate the month; the next 4 numbers indicate the year.
Store in a refrigerator (2°C - 8°C).
The reconstituted and diluted solution is stable for 24 hours at 25°C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
IVEMEND is a white to off-white powder for solution for infusion.
The powder is contained in a clear glass vial with a rubber stopper and an aluminium seal with a grey plastic flip off cap.
Each vial contains 150 mg of fosaprepitant. Pack sizes: 1 or 10 vials.
Not all pack sizes may be marketed.
Marketing Authorisation Holder:
For any information about this medicine, please contact:
This leaflet was last revised in June 2022.
© 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.